You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE

    SBC: Mitochondria in Motion, Inc.            Topic: 999

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: There are a number of rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), for which there is no available or effective therapy and which lead to significant mor ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists to prevent Charcot Marie Tooth diseaseA Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractCharcot Marie ToothCMTdisease typeA is an incurableprimarily pediatricautosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusinMFNgeneThere are currently no disease altering treatmentsMitochondria in Mot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A mobile technology to extend the reach of primary care for opioid misuse

    SBC: Rissana, LLC            Topic: NIDA

    Project Summary Opioid use disorderOUDhas reached epidemic levels in the United Stateswith catastrophic resultsmore Americans died from opioid overdoses inandthan in the entirety of the Vietnam WarPrimary care providersPCPsserve a critical role in combatting this epidemicbecause they see patients who misuse opioids but are not yet dependent in addition to those who are already dependentHoweverther ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Advancement of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)

    SBC: Accuronix Therapeutics Inc            Topic: 102

    Project Summary Abstract Pancreatic cancer is a devastating disease with a very lowyear survival rateTherapeutic options are limited in efficacy and many have substantial toxicityTargeted drug delivery may improve the therapeutic index of cancer drugs by enhancing drug localization to the cancer cell while minimizing off target side effectsreceptors are highly expressed in pancreatic and other can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesityrelated metabolic diseases constitute a significant public health burdenThe increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obeseIn additionobesity is also associated with accumulation of lipid in the liver parenchymahepat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government